United Therapeutics (UTHR) Q3 2026 Earnings Call Transcript

United Therapeutics reported record Q3 2026 revenue of $832.5 million, up 4% year over year, led by Tyvaso DPI growth of 13% to $378.5 million and Orenitram growth of 11% to $145.0 million. Net income fell 24% to $258.6 million as R&D expense rose 119% to $279.2 million and the effective tax rate increased to 31%; management also reported more than 1,000 October referrals and approved a new $2 billion repurchase authorization. The outlook includes a delayed soft-mist inhaler NDA filing, now expected in 2027, while ralinepag’s June 24, 2027 PDUFA date faces a potential supplier-compliance risk that management is working to address.

Analysis

UTHR’s stronger commercial momentum is strategically more valuable than the headline revenue growth: higher DPI dosing may lift revenue per patient and retention, while expanded field coverage could convert referrals into starts over coming quarters. But referrals are a leading indicator, not evidence of durable net adds; competitive therapies are already pressuring several products. Earnings quality is also weaker than the top line suggests: the litigation-accrual reversal flatters reported SG&A, while elevated R&D and tax expense weigh on earnings. Buybacks may support per-share results, but should not be mistaken for operating acceleration.

For LQDA, the settlement narrows the promotional opportunity for YUTREPIA in PH-ILD and reduces the near-term switching catalyst. It does not establish how much revenue is at risk; verify indication mix and commercial trends before sizing a short. UTHR’s countervailing risks are execution and timing: the SMI filing delay pushes optionality out, and the API supplier’s OAI status creates a potential ralinepag review or launch bottleneck despite contingency work. Over 6–18 months, pipeline breadth is valuable only if data, regulatory progress, and launches convert into measurable sales. The key falsifiers are a sustained acceleration in Tyvaso starts and sales, or conversely flat patient starts, further filing slippage, or an FDA action that threatens the ralinepag timeline.

Key Decisions for Investors

• Consider a modest UTHR-over-LQDA relative-value position only if current prices do not already reflect the settlement’s reduced PH-ILD competitive scope. Keep sizing conservative pending evidence on LQDA indication mix and UTHR’s net patient additions.
• Over the next 1–3 months, track Tyvaso referrals converting into starts, dose mix, and sequential sales—not referral records alone. A failure to sustain commercial conversion would weaken the growth thesis.
• Treat ralinepag as a catalyst with a material supply-chain/regulatory dependency: monitor FDA correspondence and supplier remediation. Reassess exposure if the PDUFA timeline moves or the alternative API plan proves insufficient.
• Do not capitalize the SMI opportunity on the prior filing timetable. Wait for a specific revised submission schedule and evidence the additional data work is on track; further delay is a thesis-negative.